On April 6, 2022 Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company, reported that two important milestones on advancing the speed and scale of its spatial phenotyping solutions, will be presented during the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting in New Orleans, April 8 to 13 (Press release, Akoya Biosciences, APR 6, 2022, View Source [SID1234611514]). First, the company will showcase the industry’s first 100-plex dataset for deep spatial phenotyping at single cell resolution, across an entire tissue sample. Second, they will preview a new universal chemistry to enable accelerated validation of biomarkers discovered using deep spatial phenotyping.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Powered by the high-speed imaging capabilities of PhenoCycler-Fusion, the company will showcase how a panel of 100+ markers mapped across whole slides, at single-cell resolution, can give us unprecedented insights into tumor-immune biology. In addition to the speed of imaging, the system has a proprietary file compression algorithm that can reduce file sizes from terabytes to gigabytes. This powerful combination makes it easier for cancer researchers to scale up their spatial discovery efforts with larger panels.
Complementing the 100-plex dataset, and first unveiled at Spatial Day in December 2021, the company will also preview its new universal chemistry for rapid biomarker validation. Because the 100-plex panel and universal chemistry workflows are grounded in the same barcoded antibodies, customers can discover novel biomarkers using PhenoCycler-Fusion and leverage the same chemistry to validate the resulting biomarkers on the Fusion, as a standalone system, at a capacity of 100+ samples per week. Providing cohesion and consistency of imaging methods, chemistry and data analysis will accelerate the translation of spatial discoveries into actionable biomarker signatures.
These novel datasets and customer case studies will be presented during Akoya’s Exhibitor Spotlight Theater, titled ‘Comprehensive Spatial Phenotyping: Mapping the Tumor Microenvironment at Scale’ on April 12 at 3 PM (CST).
Speakers include:
Sizun Jiang, PhD, Principal Investigator, Beth Israel Deaconess Medical Center
Bernard Fox, PhD, Harder Family Endowed Chair in Cancer Research, Earle A. Chiles Research Institute, Providence Cancer Center
Oliver Braubach, PhD, Head of Applications, Akoya Biosciences
"We are excited to demonstrate the rapid advancement of our spatial phenotyping solutions. The speed enabled by our platforms is a catalyst not just for biomarker discovery but also accelerates the pace of development of our internal R&D teams," said Brian McKelligon, Chief Executive Officer of Akoya Biosciences. "We are looking forward to sharing these latest innovations at AACR (Free AACR Whitepaper) and at the AGBT Annual Meeting in June, we will be showcasing our advancements in multiomics and spatial transcriptomics."
To view the full list of 23 abstracts and posters and to register for the Exhibitor Spotlight Theater, please visit akoyabio.com/aacr2022.